Fannin Innovation Studio

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.

Allterum Therapeutics is a biopharmaceutical company focused on developing innovative treatments for relapsed acute lymphoblastic leukemia and other cancers that express the IL-7 receptor. The company is advancing a monoclonal antibody, specifically the 4A10 antibody, which was originally developed at the National Cancer Institute and is designed to selectively target and eliminate cancer cells. This targeted approach aims to minimize the side effects commonly associated with conventional chemotherapy, particularly benefiting pediatric patients with relapsed or refractory T-cell malignancies. Additionally, Allterum Therapeutics is investigating the potential of its therapies for relapsed or refractory solid tumors characterized by IL-7R over-expression.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, specializing in the development of inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company's innovative approach focuses on enhancing the innate immune system to provide rapid and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. Pulmotect’s lead product, PUL-042, is a clinical-stage inhaled therapeutic that delivers immediate immune response, offering broad-spectrum protection that lasts for several days. By boosting the body’s natural defenses, Pulmotect aims to significantly reduce morbidity and mortality in vulnerable patient populations at risk of severe respiratory diseases.

Pulmotect, Inc. is a biopharmaceutical company based in Houston, Texas, specializing in the development of inhaled therapeutics aimed at preventing and treating respiratory infections, particularly in cancer patients with compromised immune systems. Founded in 2007, the company's innovative approach focuses on enhancing the innate immune system to provide rapid and effective protection against a wide range of pathogens, including bacterial pneumonia, influenza, and fungal pneumonia, as well as potential bioterror agents. Pulmotect’s lead product, PUL-042, is a clinical-stage inhaled therapeutic that delivers immediate immune response, offering broad-spectrum protection that lasts for several days. By boosting the body’s natural defenses, Pulmotect aims to significantly reduce morbidity and mortality in vulnerable patient populations at risk of severe respiratory diseases.

Procyrion, Inc. is a clinical-stage medical device company based in Houston, Texas, specializing in the design and manufacture of circulatory assist devices. The company has developed Aortix, a first-in-class heart pump that is deployed via catheter, providing a non-surgical solution for heart failure patients who do not respond to medication alone. Aortix is designed to alleviate symptoms of heart failure by disrupting the cardiorenal syndrome cycle, allowing the heart to rest and heal while improving blood flow to vital organs. This innovative device is notably compact, enabling cardiologists to implant it through a catheter in the leg, addressing critical needs in a population where only a small percentage of patients receive treatment due to the limitations of current solutions. Founded in 2005, Procyrion aims to enhance the quality of life for individuals suffering from heart failure, particularly those who are diuretic resistant.